A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03522246

Recruitment Status : Recruiting

First Posted : May 11, 2018

Last Update Posted : August 2, 2019

See Contacts and Locations

Sponsor:

Collaborators:

Bristol-Myers Squibb

Gynecologic Oncology Group

European Network of Gynaecological Oncological Trial Groups (ENGOT)

Foundation Medicine

Information provided by (Responsible Party):

Clovis Oncology, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	December 30, 2024
Estimated Study Completion Date :	December 30, 2030

To Top